In a phase III study of patients with moderate-to-severe osteoarthritis (OA) who had not responded to or could not tolerate standard-of-care analgesics, the nerve growth factor inhibitor tanezumab improved pain, physical function and Patient’s Global Assessment of OA (PGA-OA) at 24 weeks when administered subcutaneously at a dose of 5 mg every 8 weeks (as compared with placebo). Tanezumab 2.5 mg every 8 weeks improved pain and function but not PGA-OA, compared with placebo. Rapidly progressive OA occurred more frequently in the tanezumab 5 mg group than in the tanezumab 2.5 mg group (2.8% vs 1.4%).
References
Original article
Berenbaum, F. et al. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2019-216296 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Onuora, S. Tanezumab improves difficult-to-treat OA. Nat Rev Rheumatol 16, 296 (2020). https://doi.org/10.1038/s41584-020-0431-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-020-0431-3